04. September 2014

Boehringer Ingelheim and BeiGene announce strategic partnership agreement in China

Hubertus von Baumbach and John V. Oyler singing the strategic partnership announcement

On 2 September, Boehringer Ingelheim and BeiGene (Beijing), Co., Ltd., announced that the two companies have entered into a strategic agreement to manufacture biopharmaceuticals in China for BeiGene’s clinical oncology trials. Hubertus von Baumbach, Member of the Board of Managing Directors, David Preston,Chairman and CEO of the Boehringer Ingelheim T.C.M. region, John V. Oyler, CEO of BeiGene and several Chinese media attended the signing ceremony.


Hubertus von Baumbach commented: “We are excited to enter into this important agreement with the growing biopharmaceutical company BeiGene. Boehringer Ingelheim is a leading player in developing and manufacturing biopharmaceuticals. By bringing our experience to China, we are able to support more Chinese biopharmaceutical companies in developing and manufacturing biomedicines thus providing more medication of high quality to Chinese patients.”


BeiGene is an innovative Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics. “We are confident that Boehringer Ingelheim’s quality facilities and clinical manufacturing capabilities will be critical to helping us achieve these goals while meeting China and global requirements for quality and regulatory compliance as our pipeline continues to rapidly progress in the years ahead,” said by John V. Oyler from BeiGene at the press conference.


“Biopharmaceuticals is one of the key pillars driving our business in China,” added David Preston. “The co-operation with BeiGene is a landmark development for us.”


BI is committed to set up its China platform consisting of a tox and early clinical supply Bio-Lab, as well as a GMP facility for clinical and early commercial supply with an investment of 36 million Euro. The cGMP manufacturing site will be ready for operations early 2016.The company plans to become a leader for contract development & manufacturing of monoclonal antibodies and recombinant proteins in China and to establish a platform for Boehringer Ingelheim’s own NBEs and Biosimilars.

Contact Us

Boehringer Ingelheim BioXcellence - Contact Us

Do you have any inquiries, questions or comments? Please get in touch with us.

What Shanghai can offer you

World map showing Shanghai

Boehringer Ingelheim Biopharmaceuticals in China (whitepaper)